Home Blog Page 1218

Tulip Innovation Patent Claims Against Sunwoda Batteries Expand to Include KTC Action

By
Advertorial Desk
-

BUDAPEST, Hungary, Jan. 26, 2026 /PRNewswire/ — On 19 January 2026, the Korea Trade Commission (KTC) instituted a case based on claims filed by Tulip Innovation that Sunwoda’s lithium-ion battery cells and Geely Auto Group’s battery packs – supplied for a best-selling hybrid SUV in Korea – infringe a patent included in Tulip’s battery licensing program. This escalation of Tulip’s enforcement campaign against Sunwoda’s and its customers’ unlicensed activities follows patent actions filed in Germany and is the result of Sunwoda’s continued unwillingness to take a license.

 

The KTC action involves Korean Patent No. 10-1089135 and relates to the combination of an electrode and a battery separator, which is an important element for the safety and performance of a car battery. The asserted Korean patent is a counterpart of one of the European patents Tulip asserted in German cases that resulted in the issuance of three injunctions against Sunwoda last year.

As the licensing agent for a portfolio of over 5,000 patents owned by LG Energy Solution and Panasonic Energy, Tulip’s enforcement efforts are mainly directed at battery manufacturers but may also include customers that source batteries from unlicensed suppliers.  The newly instituted Korean case demonstrates the global strength of the Tulip portfolio and indicates that companies operating downstream in the lithium-ion battery supply chain may have patent infringement liability relating to unlicensed products.

“Tulip initiated this action in Korea as part of its commitment to uphold fair and competitive market conditions in the battery industry,” explained Ferencz Farkas, Director of Tulip, adding that “our goal is to grant licenses under the portfolio to all lithium-ion battery manufacturers but, if needed, Tulip is prepared to enforce against different participants in the supply chain to protect Licensors’ intellectual property rights.”

About Tulip Innovation

Tulip Innovation Kft. is an independent company founded to establish and manage the lithium-ion battery licensing program. Based in Hungary, the hub of European battery manufacturing, Tulip’s mission is to collaborate with companies implementing Li-ion battery technology to ensure that their manufacturing operations have access to Tulip’s robust IP portfolio.  Led by a team of licensing professionals with decades of experience, Tulip has a unique combination of strong industry connections and expertise in negotiating and administering patent licenses. Additional information is available at www.tulipinnovation.com 

Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

By
Advertorial Desk
-

–Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026.

–ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed.

HONG KONG, Jan. 26, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that the first participants have been dosed in a U.S. 13-week Phase II study (NCT07321678) with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. 

Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity (NCT07002905) in 125 participants with obesity or overweight with at least one weight-related comorbidity at multiple sites across the U.S. At the 13-week primary endpoint, ASC30 once-daily tablets showed statistically significant, clinically meaningful and dose-dependent placebo-adjusted mean body weight reductions of 5.4%, 7.0% and 7.7% for 20 mg, 40 mg and 60 mg, respectively. No plateau was observed for weight loss. The vomiting rate of ASC30 titrated weekly to target dose was approximately half of the published vomiting rate observed with orforglipron titrated weekly. The gastrointestinal tolerability of ASC30 titrated weekly was comparable to published results of orforglipron titrated every four weeks in the Phase III ATTAIN-1 study. The total treatment discontinuation rate due to adverse events for the ASC30 Phase II study for obesity or overweight was 4.8%.

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist that can be dosed once daily orally and once monthly to once quarterly subcutaneously for the treatment of obesity, diabetes and other metabolic diseases.

“Expanding ASC30’s clinical development into the large diabetes treatment market is a logical next step that provides us with another chance to highlight ASC30’s potential best-in-class profile as a once-daily oral treatment option for patients,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “We look forward to sharing topline data from the Phase II study in diabetes participants in the third quarter of 2026.”

About the U.S. Phase II Study with ASC30 for the Treatment of Diabetes

The Phase II study is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 tablets in participants with type 2 diabetes mellitus. The primary endpoint of the Phase II study is the mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo group. Secondary endpoints include the mean change from baseline in fasting blood glucose up to 13 weeks in the treatment group compared with the placebo group, the mean change from baseline in body weight up to 13 weeks in the treatment group compared with placebo group, and safety and tolerability. The Phase II study will enroll approximately 100 participants with type 2 diabetes mellitus at multiple sites across the U.S. Participants will be randomly assigned in a ratio of approximately 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 will be titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard

By
Advertorial Desk
-

TIANJIN, China, Jan. 26, 2026 /PRNewswire/ — In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency’s Master File acknowledgement letter, issued on January 9, 2026, incorporates the “Tasly 3P Characterization of MSCs Assay” (MF 32345) into its regulatory framework. This step provides long-sought guidance to ensure the consistent, safe, and effective clinical use of MSCs.

FDA Device Master File Information
FDA Device Master File Information

Historically misclassified as stem cells, MSCs have been associated with variable clinical outcomes due to a lack of specific quality benchmarks. The newly recognized ” 3P ”  assay directly addresses this by evaluating three core attributes: Property (cell identity), Purity (freedom from contaminants), and Potency (functional activity). This focus ensures that therapeutic MSC products are accurately defined, devoid of heterogeneous cell populations, and biologically potent. The introduction of the Tasly 3P assay marks a pivotal shift toward normalized characterization of MSCs. It mitigates historical risks such as tumor formation and therapeutic inconsistency while empowering clinicians and patients to verify cell quality before treatment. As the first FDA-recognized protocol of its kind, it establishes a new benchmark for the field and accelerates the transition in regenerative medicine from a stem-cell-centric model to a stromal cell-focused paradigm.

By endorsing a standard that aligns with the modern scientific understanding—that MSCs primarily function via paracrine signaling, not differentiation—the FDA is closing a critical regulatory gap. This alignment with updated International Society for Cell & Gene Therapy guidelines is poised to streamline Investigational New Drug applications, enhance clinical trial reliability, and foster global harmonization in MSC product evaluation.

 

Hivemind Capital and CPIC Investment Management Announce Strategic Partnership to Establish $500 Million Real-World Asset Tokenization Fund

By
Advertorial Desk
-

HONG KONG, Jan. 26, 2026 /PRNewswire/ — Hivemind Capital, a global investment group focused on the intersection of traditional markets and the onchain economy, today announced a strategic partnership with CPIC Investment Management (H.K.) Co, Ltd (“CPIC IMHK”), an affiliate of one of the world’s largest insurance groups, to establish a real-world asset tokenization fund strategy.

The initiative brings together Hivemind’s expertise in digital asset market structure and operations with CPIC IMHK’s deep institutional distribution network and trusted, regulated presence in Hong Kong. The fund platform is designed to enable the compliant tokenization of select real-world assets, broaden institutional access, and support yield optimization under rigorous regulatory and risk management standards.

Hivemind will serve as investment manager, overseeing portfolio construction, risk management, and execution, conducted outside Hong Kong, while CPIC IMHK will support advisory, distribution, and institutional investor engagement in Hong Kong under its existing regulatory licenses. The PAC, a RWA issuance platform incubated by CPIC IMHK is expected provide tokenization services. Together, the firms aim to combine onchain investment infrastructure with established asset management practices to deliver transparent, compliant, and institutionally aligned tokenized investment products. The platform is designed with an initial target capacity of up to $500 million, subject to market conditions, investor demand from institutional and other non-retail eligible counterparties, and applicable regulatory approvals.

“Real-world asset tokenization represents a practical evolution in how traditional assets are managed,” said Matt Zhang, Founder of Hivemind. “We believe partnering with a world-renowned institutional investor like CPIC IMHK allows us to combine onchain investment expertise with a trusted, institutionally scaled distribution platform, bringing more assets onchain and expanding institutional access to blockchain-based markets.”

CG Zhou, CEO of CPIC IMHK added, “Tokenization represents a new way to improve how institutional capital is deployed and managed. Working with Hivemind allows us to apply this technology to enhance transparency, efficiency, and return potential, while maintaining the regulatory and governance standards expected by our investors.”

The initiative reflects growing institutional demand for tokenized access to traditional assets, particularly private assets, which have the potential to enhance transparency, improve liquidity, and expand avenues for increased return. By focusing on compliance-first implementation and institutional distribution, the partnership seeks to support the responsible adoption of tokenization as part of the broader continued evolution of global financial markets.

About Hivemind Capital

Hivemind Capital Partners is a global investment group operating at the intersection of traditional finance and the onchain economy. Founded in 2021, Hivemind allocates institutional capital across a diverse set of investment strategies, and implements technology infrastructure to help assets and institutions transition onto blockchain rails with discipline, durability, and scale.

Learn more at hivemind.captial.

About CPIC IMHK

CPIC IMHK holds Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (providing asset management) licenses from the Securities and Futures Commission of Hong Kong (the “SFC”), and is engaged in three main types of business: dealing in securities, advising on securities and providing asset management. CPIC IMHK partners closely with clients in pursuit of the best investment solutions, powered by the strong backing of our shareholders, a dynamic culture, top-tier talent, and robust operational processes, it offers bespoke investment solutions across global financial markets, thoughtfully designed to meet the diverse and evolving needs of our clients.

In March 2025, CPIC IMHK was approved by the SFC to launch a tokenized US dollar-denominated currency fund. As one of the first institutions to bring such an innovative product to market, CPIC IMHK is at the forefront of advancing the tokenization of traditional currency funds – laying a solid foundation and offering a premium, institution-grade underlying asset for future stablecoin initiatives.

The Billion Dollar Brushstroke: Attorney’s art platform secures $1B+ in committed listings in first month – positioned for rapid growth.

By
Advertorial Desk
-

DUBAI, UAE, SYDNEY and NEW DELHI, Jan. 26, 2026 /PRNewswire/ — An entertainment and creative arts lawyer’s bold vision for a revolutionary online art auction platform, Lloyds Auctions, launched on January 1, 2026, and has already secured over $1 billion in committed art listings, including more than 3000 pieces within its first few weeks, positioning it as one of the fastest-growing art-tech platforms in history.

Mr. Cassin examines the sculptural depth of F.N. Souza’s impasto of a vibrant cityscape, where every line and heavy stroke affirms the artist’s status as India’s Picasso.
Mr. Cassin examines the sculptural depth of F.N. Souza’s impasto of a vibrant cityscape, where every line and heavy stroke affirms the artist’s status as India’s Picasso.

Giuseppe Cassin spent more than a decade closing multimillion-dollar deals for filmmakers, artists, directors, and collectors. Frustrated by the art world’s outdated, old-world system – high fees, invitation-only sales, and persistent integrity issues – he developed a game-changing idea: a digital-first platform that does for authenticated art what Uber did for taxis.

It connects sellers directly to a global audience with rigorous authentication, high-end curation, transparent fees, and real-time bidding open to anyone, anywhere. “We’re giving every artist, collector, and seller the same global access that only a handful enjoyed before,” said Giuseppe Cassin, Founder: Lloyds Creative Arts.

Cassin pitched the concept to investors and secured heavy backing from leading online auction house Lloyds Auctions. The platform officially launched on January 1, 2026, with its first dedicated online auction going live in mid-January, featuring a headline collection of 30 Southeast Asian Masters including works from masters such as MF Husain, FN Souza, Manjit Bawa, and Vasudeo S. Gaitonde with estimates in the tens of millions. The response was immediate and strong: sellers and collectors flooded in.

In just its first few weeks of trading, the platform has locked in over $1 billion worth of committed art listings, spanning blue-chip masters to emerging talents. “Our mission is to make art accessible to everyone in a safe, non-intimidating way,” Mr. Cassin continued. “With every work rigorously verified and independently authenticated – including by an expert of the buyer’s choice – bidders and buyers bid with a higher level of confidence, especially on master’s and other ultra-high-value art categories. At the same time, emerging artists get immediate global exposure and real-time feedback from customers on what resonates with their work.”

The platform’s rapid rise has drawn strong interest from investors and industry insiders, who now see unicorn status (a $1 billion+ valuation) as a realistic next milestone. Should it reach that mark, it would rank among the quickest ascents since Canva.

The platform continues to receive new artists and collectors every day, with fresh auctions launching regularly.

Discover the platform and view the current auction at lloydsauctions.com/art

About:
The platform launched on January 1, 2026, with major investment from leading online auction house Lloyds Auctions, the platform is a digital-first global marketplace for fine art, combining expert curation, rigorous independent written authentication, and an intuitive interface to make buying and selling art seamless, transparent, and accessible to everyone.

V. S. Gaitonde’s rare abstract masterpiece invites a state of profound meditation, where layered surfaces and silent tonal shifts transcend visual art to become an experience of pure inner stillness.
V. S. Gaitonde’s rare abstract masterpiece invites a state of profound meditation, where layered surfaces and silent tonal shifts transcend visual art to become an experience of pure inner stillness.

F.N. Souza’s architectural cityscape channels raw, brooding intensity through sharp angles and visceral textures, transforming a medieval-inspired vista into a powerful psychological landscape.
F.N. Souza’s architectural cityscape channels raw, brooding intensity through sharp angles and visceral textures, transforming a medieval-inspired vista into a powerful psychological landscape.

M.F. Husain, Horses (2006), Acrylic on Canvas, 97 x 60 in; a monumental composition of bold, angular forms and striking colors capturing the raw power of horses charging beyond the frame.
M.F. Husain, Horses (2006), Acrylic on Canvas, 97 x 60 in; a monumental composition of bold, angular forms and striking colors capturing the raw power of horses charging beyond the frame.

Manjit Bawa’s 1998 masterpiece from his Krishna series, captures a meditative harmony through its iconic ochre backdrop and sculptural simplicity.
Manjit Bawa’s 1998 masterpiece from his Krishna series, captures a meditative harmony through its iconic ochre backdrop and sculptural simplicity.

DPC Dash-Domino’s Pizza China Hits Symbolic Milestone: 1,405th Store Opens in Sanya, Matching Its HKEX Stock Ticker

By
Advertorial Desk
-

HONG KONG, Jan. 26, 2026 /PRNewswire/ — Domino’s Pizza China (“DPC Dash” or the “Company”) (1405.HK), the exclusive master franchisee for Domino’s Pizza in the Chinese Mainland, Hong Kong SAR, and Macau SAR, today announced the opening of its 1,405th store in the city of Sanya, in southern Hainan Province. The milestone was achieved on January 24, 2026, marking a symbolic milestone as the store count matches the Company’s stock ticker on the Hong Kong Stock Exchange (HKEX).

Hainan is the southernmost province of China that’s known for its tropical climate, beach resorts and forested, mountainous interior, and is sometimes called “China’s Hawaii.” With the addition of Sanya, as of January 24, 2026, the Company has now entered 72 cities in the Chinese Mainland.

The milestone store opening comes on the heels of DPC Dash’s exceptional 2025 performance, during which the Company successfully achieved its full-year store expansion targets and strengthened its leading position in China’s pizza market. Throughout 2025, DPC Dash added 307 net new stores and expanded into 21 new cities, bringing its total footprint to 60 cities across the Chinese Mainland as of December 31, 2025.

Reaching 1,405 stores – a number that mirrors DPC Dash’s stock ticker – is more than a numerical coincidence; it represents the convergence of the Company’s operational excellence and market confidence in its development path. This milestone reflects the success of the Company’s ‘go broader, go deeper’ store network expansion strategy and the strong consumer demand for the Domino’s Pizza brand across the Chinese Mainland’s highly diverse markets.

Moving forward, DPC Dash will continue to deepen its 4D strategy of Development, Delicious Pizza at Value, Delivery, and Digital, exploring China market consumption potential while maintaining innovation and sustainable operations to provide Chinese consumers with exceptional value and deliciousness.

About DPC Dash

DPC Dash is Domino’s Pizza’s exclusive master franchisee in the Chinese Mainland, the Hong Kong Special Administrative Region of China and the Macau Special Administrative Region of China. Domino’s Pizza, Inc., DPC Dash’s global franchisor, is one of the most widely-recognized global consumer brands and the world’s largest pizza company. Led by a seasoned and visionary management team, DPC Dash is a market leader that differentiates from competitors with, among others, a continually innovated and localized pizza-focused menu, unique expertise and leadership in delivery, technology focus and scalable and replicable store economic model. DPC Dash operates 1,315 stores in 60 cities in the Chinese mainland as of December 31, 2025.

For more information, please visit www.dpcdash.com
For official company announcements, please visit www.hkexnews.hk

Contacts

DPC Dash Ltd Investor Relations:

DPC Dash Ltd
IR@dominos.com.cn

ICR, LLC
dpcdashIR@icrinc.com 

DPC Dash Ltd Media Relations:

ICR, LLC
dpcdashPR@icrinc.com

Clarification Regarding Unitree’s 2025 Sales Data

By
Advertorial Desk
-

HANGZHOU, China, Jan. 25, 2026 /PRNewswire/ — Unitree Robotics, a global leader in general-purpose robotics development, issued an official clarification regarding its 2025 sales and shipment figures on January 22, 2026, in response to misinformation circulating online.

The company’s full statement is as follows:

Clarification Regarding Unitree’s 2025 Sales Data

  1. Over the past month, many pieces of misinformation regarding our company’s 2025 shipment volume have been circulating online. Unitree has never previously disclosed any sales data of 2025 externally. We appreciate everyone’s attention.
  2. In 2025, Unitree’s actual shipment volume of humanoid robots exceeded 5,500 units (referring to the quantity actually sold and delivered to end customers, not order volume; the order volume is higher). The total mass-production output of 2025 exceeded 6,500 units.
  3. The aforementioned figures consist solely of our pure humanoid robots and do not include our dual-arm wheeled robots or any other robots.
  4. Currently, given the diversity of robotic forms, we suggest not to directly combine the numbers of different types of robots together for comparison.

                                                                 January 22, 2026

About Unitree Robotics

Unitree Robotics is a world-renowned civilian robotics company, which is focusing on the R&D, production, and sales of consumer and industry-class high-performance general-purpose legged and humanoid robots, six-axis manipulators, and so on.

Baseus Launches New Nomos II Charging Station to Deliver Powerful, Tidy, Multi-Device Charging

By
Advertorial Desk
-

SHENZHEN, China, Jan. 25, 2026 /PRNewswire/ — Guided by its user-centric philosophy, Baseus — a global leader in consumer electronics and smart charging solutions — today announced the launch of new charging stations in its Nomos II series: a 6-in-1 245W model. Designed to address the evolving needs of modern users, the new products combine powerful performance with practical, reliable, and stylish design.

Tailored to professionals such as programmers, creators, and desk setup enthusiasts, the Nomos II series chargers address common multi-device charging challenges, including tangled cables, limited ports, and unstable power. With high power capacity and innovative integrated cable design, the series delivers efficient, reliable, and clutter-free charging for multiple devices. The cables extend flexible reach and retract neatly to keep desks organized, making Nomos II ideal for home offices, professional setups, and mobile work environments where both performance and workspace aesthetics matter.

Baseus Nomos NH21 6-in-1 Desktop Charging Station (Left) Baseus Nomos NH21 5-in-1 Desktop Charging Station (Right)
Baseus Nomos NH21 6-in-1 Desktop Charging Station (Left) Baseus Nomos NH21 5-in-1 Desktop Charging Station (Right)

Baseus Nomos NH21 6-in-1 Desktop Charging Station with Dual Retractable Cables 245W

The 245W Nomos model serves as a comprehensive desktop energy hub, featuring dual 0.8m braided USB-C retractable cables, two additional USB-C ports, one USB-A port, and Qi2 magnetic wireless charging, supporting up to six devices simultaneously.

Normally, desktop chargers require users to carry and plug in extra cables, which often leads to tangled cords, cluttered desks, and limited reach. To address this pain point, Baseus introduces an innovative integrated design with two retractable USB-C cables that extend securely for flexible reach and retract neatly when not in use — replacing messy traditional cords while withstanding over 35,000 pulls for lasting durability.

Delivering up to 245W total output, including dual USB-C ports capable of 140W each, the Nomos NH21 applies BPS 3.0 intelligent power distribution to automatically allocate power across connected devices for optimal efficiency and safety. Its advanced GaN technology ensures higher power delivery in a cooler, more reliable form factor. Unlike conventional chargers that concentrate heat in the main body, the 6-in-1 245W model adopts a split design that effectively disperses thermal load to the power adapter, enabling stable, high-wattage charging for multiple devices simultaneously. A built-in digital display further enhances usability with real-time power and current monitoring.

The charger is compatible with a wide range of devices, including smartphones, tablets, laptops, and cameras — such as iPhone 12–17, MacBook, MateBook, Galaxy, iPad, Switch, DJI, and GoPro. It also supports Qi2 wireless charging for the iPhone 12–17.

Baseus Nomos NH21 5-in-1 Desktop Charging Station with Retractable Cable 160W

As a Nomos II-generation product launched in H2 2025, the 160W 5-in-1 Nomos II offers a compact desktop charging solution with one 0.8m braided retractable USB-C cable, two additional USB-C ports, one USB-A port, and Qi2 wireless charging, supporting up to five devices simultaneously. 

Both models are designed for seamless usability, enabling instant plug-and-charge convenience without the need for extra adapters or setup, further simplifying multi-device power management and empowering modern professionals to maintain efficient, clutter-free workspaces.

Price and Availability

  • Baseus Nomos NH21 6-in-1 Desktop Charging Station with Dual Retractable Cables (245W): MSRP $179.99 (U.S.) / €129.99 (EU). Available online via Amazon U.S. and Amazon EU, and offline at MMK (Spain), Yodobashi and Bic Camera (Japan), and Best Buy (U.S.) starting from January 2026.

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users’ problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products – including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users’ sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:

Name: Baseus PR Team
Phone: +1 (213) 512-7063
Email: pr@baseus.com
Baseus Technology (HK) Co., Ltd

1...1,2171,2181,219...6,484Page 1,218 of 6,484